CAR T Cell Therapy Market | Growing Industry Crucial Key Players - Novartis International, Kite Pharma, Juno Therapeutics, Celgene Corporation, Cellectis, Sorrento Therapeutics, Bluebird bio

CAR T Cell Therapy Market Potential: A Significant Scope for the Treatment of Blood Cancer

The report " CAR T Cell Therapy Market [By Target Antigen (CD19, CD20, MESO, HER2, EGFRV III, and Others); By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, and Others); and By Regions]: Market size & Forecast, 2018 – 2025."
The global CAR T Cell Therapy market is anticipated to reach USD 2,998.1 Million by 2025 from USD 149.3 Million in 2017, at a CAGR of 45.6% during the forecast of 2018-2025.

To know about the assumptions considered for the study, get the sample pdf brochure- https://www.polarismarketresearch.com/industry-analysis/CAR-T-Cell-Therapy-Market/request-for-free-sample

CAR-T (Chimeric Antigen Receptor) cell therapy comprises re-engineering cancer patient's white blood cells (WBC) to fight the malignant cells by recognizing them. During this therapy, the person’s T cells are extracted, preciously reformed and then inserted again to the person's body where the restructured cell multiply and target cancer cells. Increasing cancer cases are anticipated to increase the demand for reliable and effective therapeutic treatment approach for enhancement of quality of person’s life.

Accumulative levels of acquisitions as a part of innovative research and the increasing importance of cellular therapies are estimated to significantly boost the market growth. As per the current market scenario, Novartis and Gilead are leading key players of CAR-T with their first therapies approved in pediatric Acute Lymphoblastic Leukemia (ALL) and adult Diffuse Large B-cell Lymphoma (DLBCL).

Key Players

The major players involved in global CAR T Cell Therapy market are Novartis International AG, Kite Pharma, Inc., Juno Therapeutics, Pfizer, Inc. Celgene Corporation, Cellectis, Sorrento Therapeutics, Bluebird bio, and Immune Therapeutics. Leading pharmaceutical players are accelerating their involvement through merger & acquisitions, and partnerships to gain entrance into ground-breaking technologies for the cancer treatment. Novartis and Gilead are leading players of CAR-T with their first therapies approved in pediatric Acute Lymphoblastic Leukemia (ALL) and adult Diffuse Large B-cell Lymphoma (DLBCL).

Browse Complete Summary of this report with in-depth TOC @ https://www.polarismarketresearch.com/industry-analysis/CAR-T-Cell-Therapy-Market/

Novartis and Kite (a US-based subsidiary of Gilead) are the first to reach the US market and expected to enhance the number of academic centers that can deliver appropriate treatment during the forecast period. As a part of this strategy, Gilead announced 28 centers authorized to treat patients with Yescarta and Novartis has announced 33 centers that are certified to treat patients with Kymriah. This is expected to enhance the company’s global portfolio including their commercial model for the therapies, and reimbursement modalities.

Key Take-away

• Based on target antigen, CD19 is estimated to dominate the CAR T Cell Therapy market.

• Diffuse Large B-Cell Lymphoma, to hold the dominating position for application type during the forecast period.

• North America region holds major market share by geography.

Market Segmentation

• Target Antigen

o CD19
o CD20
o MESO
o HER2
o EGFRV III
o Others

• Application

o Acute Lymphoblastic Leukemia
o Diffuse Large B-Cell Lymphoma
o Follicular Lymphoma
o Chronic Lymphocytic Leukemia
o Multiple Myeloma
o Others.

• Regions

o North America
o Europe
o Asia Pacific

For more information Make Inquiry @ https://www.polarismarketresearch.com/industry-analysis/CAR-T-Cell-Therapy-Market/inquire-before-buying

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.

Contact us

Mr. Neel
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: neel@polarismarketresearch.com
Web: www.polarismarketresearch.com

This release was published on openPR.